What is this study studying for non-small-cell lung cancer?

This study is collecting real-world data on older adults with non-small-cell lung cancer receiving standard or innovative first-line treatments. It aims to understand their health, treatment approaches, and outcomes including quality of life. The research is sponsored by GFPC Investigation to improve knowledge in this patient group.

Who may be eligible for this non-small-cell lung cancer clinical trial?

Adults aged 70 years or older with non-small-cell lung cancer who have not yet received systemic anticancer treatment may be eligible. Participants must be covered by social security, able to understand the study, and eligible for systemic treatment. Please review eligibility criteria for more details.

Is there any cost to participate in this non-small-cell lung cancer clinical trial?

Study-related care, including study procedures and all trial visits, is provided at no cost. However, personal travel expenses or other costs may vary and are not guaranteed to be covered.

Actively Recruiting

Phase 4

Age: 70Years +

All Genders

ID06646471

PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly with Thoracic Tumors including Non-Small-Cell Lung Cancer

Led by GFPC Investigation · Updated on 2026-04-29

500

Participants Needed

Research Sites

104 weeks

Total Duration

AI-Summary

What this Trial Is About

Researchers are collecting real-life data on patients aged 70 years and older who are receiving first-line treatment for thoracic tumors, specifically Non-Small-Cell Lung Carcinoma, following standards defined by the European Society for Medical Oncology. The study aims to characterize participants geriatric health, biology, and cancer features, as well as to describe treatment methods and assess outcomes such as efficacy, safety, and quality of life. Exploratory subgroups treated with the same drug or innovative strategies will also be identified. Participants will undergo systemic treatment for their lung cancer according to current standard care or innovative therapies. Blood samples will be collected before the first treatment for biobanking, and tumor samples will be sent for central analysis. Patients will attend clinic visits as per usual care and will complete three quality of life questionnaires during the study. Throughout the study, participants will have regular visits and tests to monitor their general condition and treatment effects. This includes lab tests, imaging, re-biopsies, and assessments tailored for older adults. Quality of life is measured at several time points using validated questionnaires. The main outcome being tracked is progression-free survival up to two years, along with other outcomes like response rates, overall survival, safety events, and geriatric interventions. Participants may be followed for up to two years in total.

CONDITIONS

Brief Title

PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies

Who Can Participate

Age: 70Years +

All Genders

Eligibility Criteria

You may qualify if you...

Patient is 70 years or older
Diagnosed with non-small-cell lung cancer requiring systemic treatment regardless of cancer stage
No prior systemic anticancer treatment for bronchial cancer
Covered by social security
Eligible for systemic treatment
Systemic treatment must be authorized and available in routine care or early/compassionate access
Able to understand the study protocol
Not opposed to data collection about themselves
Signed informed consent form

You will not qualify if you...

Under guardianship or curatorship
Not under care or monitoring by the investigating center
Previously treated with systemic therapy for non-small-cell lung cancer

Research Team

Romain CORRE, Medical Doctor

Soizic FERLANDIN

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here